<DOC>
	<DOCNO>NCT01736683</DOCNO>
	<brief_summary>The primary objective study determine safe , tolerable effective dose sotatercept result great frequency improvement anemia patient diagnose low- intermediate-1 risk MDS non-proliferative chronic myelomonocytic leukemia ( CMML ) .</brief_summary>
	<brief_title>Study Sotatercept Treatment Anemia low-or Intermediate-1 Risk Myelodysplastic Syndromes ( MDS ) Non-proliferative Chronic Myelomonocytic Leukemia ( CMML )</brief_title>
	<detailed_description>Following enrollment initial 3 arm ; additional cohort 20 patient intermediate cohort ( exceed 2.0 mg/kg ) may add time dose escalation 1.0 mg/kg 2.0 mg/kg ( eg , 0.75 mg/kg 1.5 mg/kg respectively ) base assessment Steering Committee available safety efficacy data least six subject least three cycle treatment current dose level .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Leukemia , Myelomonocytic , Acute</mesh_term>
	<mesh_term>Leukemia , Myelomonocytic , Chronic</mesh_term>
	<mesh_term>Immunoglobulin G</mesh_term>
	<criteria>Men woman ≥ 18 year age Documented diagnosis myelodysplastic syndrome ( MDS ) nonproliferative chronic myelomonocytic leukemia ( CMML ) , White blood cell ( WBC ) ≤ 13,000 /mm3 , World Health Organization ( WHO ) ) meet International Prognostic Scoring System ( IPSS ) criteria low intermediate1 risk disease Anemia define require transfusion ≥ 2 unit red blood cell ( RBCs ) within 84 day enrollment hemoglobulin ( Hgb ) ≤ 9.0 g/dL No response loss response ErythropoiesisStimulating Agents ( ESAs ) erythropoetin ( EPO ) &gt; 500 mU/ml No response loss response great 2 prior line treatment myelodysplastic syndrome ( MDS ) nonproliferative chronic myelomonocytic leukemia ( CMML ) include ESAs line discontinue due intolerance . Eastern Cooperative Group ( ECOG ) score ≤ 2 . Adequate renal function reflect creatinine &lt; 1.5 X Upper Limit Normal ( ULN ) creatinine clearance 50 ml/min accord CockcroftGault formula Total bilirubin ≤3.0 mg/dL Aspartate aminotransferase ( AST ) /Serum glutamic oxaloacetic transaminase ( SGOT ) &amp; alanine aminotransferase ( ALT ) /serum glutamic pyruvic ( SGPT ) ≤3.0 x Upper Limit Normal ( ULN ) Free metastatic malignancy ( myelodysplastic syndrome ( MDS ) ) ≥ 2 year Patients MDS chromosome 5q deletion without document treatment failure lenalidomide ( ie , loss response response 4 month treatment , intolerable treatment , cytopenia precluding use treatment ) . Pregnant breast feed woman male agree use condom sexual contact female childbearing potential . Major surgery within 30 day Incomplete recovery incomplete heal wound previous surgery Heart failure ≥3 ( New York Heart Association ( NYHA ) ) Thromboembolic myocardial infarction event within 6 month Subjects require ongoing anticoagulant therapy course study . Aspirin allow . Concurrent anticancer cytotoxic chemotherapy History severe allergic anaphylactic reaction hypersensitivity recombinant protein Known positive human immunovirus ( HIV ) infectious hepatitis type C active infectious hepatitis type B. Clinically significant anemia unrelated myelodysplastic syndrome ( MDS ) Thrombocytopenia ( &lt; 30,000/uL ) Uncontrolled hypertension Treatment another investigational drug device within 28 day prior Day 1 Prior Exposure sotatercept ( ACE011 ) Any serious medical condition , lab abnormality psychiatric illness</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>ACE-011</keyword>
	<keyword>anemia</keyword>
	<keyword>dose-ranging</keyword>
	<keyword>intermediate-1 risk myelodysplastic syndrome</keyword>
	<keyword>low risk myelodysplastic syndrome ( MDS )</keyword>
	<keyword>multicenter</keyword>
	<keyword>open-label</keyword>
	<keyword>parallel</keyword>
	<keyword>phase 2</keyword>
	<keyword>randomize</keyword>
	<keyword>Sotatercept</keyword>
	<keyword>Non-proliferative chronic myelomonocytic leukemia ( CMML )</keyword>
	<keyword>hemoglobin</keyword>
	<keyword>transfusion</keyword>
</DOC>